Please wait while we open this resource.
K
Clinical reviews
LONG-ACTING B-2 AGONISTS (LABA) OR LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA): WHICH ONE MAY BE THE FIRST OPTION IN GROUP A COPD PATIENTS?
Onur Turan, Nalan Ogan, Fulsen Bozkus, Nurhan Sarioğlu, Pakize Ayşe Turan, Celal Satıcı
PDF20247 pages656 KB
Long-acting muscarinic antagonists (LAMA) and beta-2 agonists (LABA) are both recommended for symptom control in group A COPD patients according to GOLD guidelines. This study evaluates the effectiveness of these treatments by analyzing data from 76 patients who were new users of either LAMA or LABA. The results show that patients using LAMA had a greater improvement in their COPD Assessment Test (CAT) scores compared to those using LABA, suggesting that LAMA may be the preferred first-line treatment option in this patient group.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
CHALLENGES OF SARCOIDOSIS AND ITS MANAGEMENT
Same clinical topic · Pulmonology
THE NEW ERA OF ADD-ON ASTHMA TREATMENTS: WHERE DO WE STAND?
Same clinical topic · Pulmonology
PLEURAL EFFUSION IN CRITICALLY ILL PATIENTS AND INTENSIVE CARE SETTING
Same clinical topic · Pulmonology
OBESITY AND ACUTE PULMONARY EMBOLISM
Same clinical topic · Pulmonology
Management of Life-Threatening Asthma
Same clinical topic · Pulmonology
Management of Life-Threatening Asthma
Same clinical topic · Pulmonology
INTERSTITIAL LUNG DISEASES
Same clinical topic · Pulmonology
DIAGNOSTIC ACCURACY OF CHEST X-RAY SCREENING FOR SILICOSIS: A SYSTEMATIC REVIEW, META-ANALYSIS AND MODELLING STUDY
Same clinical topic · Pulmonology
Definitions of non-response and response to biological therapy for severe asthma: a systematic review
Same clinical topic · Pulmonology